Roy U K, Pan S
Department of Obstetrics and Gynaecology, Sambhunath Pandit Hospital, Calcutta.
J Indian Med Assoc. 1993 Jan;91(1):8-10.
Effectiveness of nifedipine in suppressing premature uterine activity was studied on 20 normal pregnant women who received, depending on the frequency of uterine contractions and degree of cervical dilatation, 5-10 mg nifedipine orally 8 hourly till the uterine contractions were abolished followed by 5 mg 12 hourly up to 38 weeks of gestation. Another 20 age, gravida and gestational period matched normal pregnant women received 10 mg isoxsuprine hydrochloride orally 8 hourly till the uterine contractions were abolished, followed by 10 mg 12 hourly up to 38 weeks of gestation. Successful tocolysis was observed in 85% of cases receiving nifedipine in contrast to 40% of women receiving isoxsuprine hydrochloride. The mean time from presentation to delivery and mean birth weight were 21.8 days and 2510 g respectively in isoxsuprine hydrochloride treated cases and 34.2 days and 2750 g respectively in cases treated with nifedipine. In either group there were no serious untoward effects on mother, labour and baby.
对20名正常孕妇进行了硝苯地平抑制子宫过早活动有效性的研究。根据子宫收缩频率和宫颈扩张程度，这些孕妇每8小时口服5 - 10毫克硝苯地平，直至子宫收缩停止，随后每12小时口服5毫克，直至妊娠38周。另外20名年龄、孕周和妊娠期相匹配的正常孕妇，每8小时口服10毫克盐酸异克舒令，直至子宫收缩停止，随后每12小时口服10毫克，直至妊娠38周。接受硝苯地平治疗的病例中85%观察到成功的宫缩抑制，而接受盐酸异克舒令治疗的女性中这一比例为40%。盐酸异克舒令治疗的病例从就诊到分娩的平均时间和平均出生体重分别为21.8天和2510克，硝苯地平治疗的病例分别为34.2天和2750克。两组中对母亲、分娩和婴儿均未出现严重不良影响。
